Skip to content
Open in App
Teva Pharmaceutical Industries DRC logo

Teva Pharmaceutical Industries DRC

web2

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic...

Symbol · TEVA
Company profile

About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

FDA target action date for BXCL501 outpatient agitation indication

KEY STEP

The FDA assigned November 14, 2026 as the target action date for BXCL501, a dexmedetomidine sublingual film under review for potential use at home for acute agitation associated with schizophrenia or bipolar I or II disorder in adults. Teva’s access to the asset remains contingent on prevailing in the court supervised sale process and completing the transaction.

Roadmap reference
People

Company team

SJ

Sol J. Barer

Independent Chairman of the Board

Company leadership profile.

RD

Richard D. Francis

President, CEO & Director

Company leadership profile.

RA

Rosemary A. Crane

Independent Director

Company leadership profile.

GM

Gerald M. Lieberman

Independent Director

Company leadership profile.

RA

Roberto Agostino Mignone

Independent Director

Company leadership profile.

AE

Amir Elstein

Independent Director

Company leadership profile.

PD

Perry D. Nisen

Independent Director

Company leadership profile.

RS

Ronit Satchi-Fainaro

Independent Director

Company leadership profile.

TZ

Tal Zaks

Independent Director

Company leadership profile.

CL

Chen Lichtenstein

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Teva Pharmaceutical Industries DRC.

Orbitrum research

Experts evaluating Teva Pharmaceutical Industries DRC

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment